<DOC>
	<DOCNO>NCT00882089</DOCNO>
	<brief_summary>The purpose study determine Contura catheter avoid radiation `` hot spot '' skin improve tissue-balloon conformance early-stage breast cancer patient undergo accelerate partial breast irradiation .</brief_summary>
	<brief_title>Use Contura™ Catheter Intermediate-Risk , Pathological Stage 0 , I , II ( Up 3.0 cm ) Breast Cancer Patients</brief_title>
	<detailed_description>In approximately 20 % patient consider accelerated partial breast irradiation ( APBI ) , balloon-to-skin distance range 3-6 mm . The Contura applicator 5 source lumen . In contrast , MammoSite catheter single source lumen . The ability choose multiple source lumen Contura catheter allow one avoid radiation `` hot spot '' skin case balloon-to-skin space 3-6 mm . Another limitation MammoSite catheter one improve suboptimal conformance balloon surround breast tissue . An air/fluid pocket next balloon push breast tissue great risk harbor residual disease away radioactive source . With APBI , plan target volume plan evaluation ( PTV_EVAL ) define breast tissue volume bound uniform expansion balloon radius dimension 10 mm less balloon volume . PTV_EVAL limit 5 mm skin surface posterior breast tissue extent ( chest wall pectoralis muscle exclude ) . The volume air/fluid pocket usually 4.8 % ± 1.1 % ( mean ± standard error ) PTV_EVAL . The Contura applicator vacuum lumen 2 opening adjacent balloon allow air/fluid removal . By use vacuum lumen Contura applicator , one typically decrease size air/fluid pocket one third . In approximately 90 % Contura patient , volume air/fluid pocket around balloon reduce less equal 3.0 % PTV_EVAL . In contrast , volume air/fluid pocket around balloon le equal 3.0 % PTV_EVAL half MammoSite patient . Since study address intermediate-risk patient , particularly important size air/fluid pocket minimize Contura applicator . SenoRx , Inc. ( Aliso Viejo , CA ) currently conduct registry study Contura MLB applicator `` low-risk '' patient population . This `` intermediate-risk '' study complimentary low-risk registry study . There overlap patient eligibility . Intermediate-risk patient meet follow criterion : 1 . Age 18-49 year , 2 . Estrogen receptor-negative progesterone receptor-negative breast cancer , 3 . 1-3 involved axillary lymph node</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Patients invasive breast cancer require axillary stag include sentinel node biopsy alone sentinel node negative axillary dissection sample minimum total 6 axillary node sentinel node positive . Axillary staging require patient DCIS . Estrogen receptor ( ER ) progesterone receptor ( PR ) analysis must negative . The patient must ≥ 18 year old . If patient old 49 year , must meet least one follow 2 condition : . 13 histologically positive axillary node ii . negative ER PR analysis The patient life expectancy least 10 year , exclude diagnosis breast cancer . The tumor must DCIS invasive adenocarcinoma breast . Gross disease must unifocal pathologic tumor size 3.0 cm less . Patients microscopic multifocality eligible long total pathologic tumor size 3.0 cm less . The patient must pathological stage 0 , I , II breast cancer . Surgical treatment breast must lumpectomy . The margin resect specimen must histologically free tumor ( DCIS invasive ) . Reexcision surgical margin permit . The patient must register within 42 day follow last surgery breast cancer . The target lumpectomy cavity/whole breast reference volume must ≤ 30 % base postoperative CT scan . The patient &lt; 18 year old . If patient old 49 year , ER PR positive tumor histologically negative axillary node . T2 ( &gt; 3.0 cm ) , T3 , stage III , stage IV breast cancer . `` Marginal '' `` borderline '' ER PR analysis result . More 3 histologically positive axillary node . Axillary node definite evidence microscopic macroscopic extracapsular extension . One positive nonaxillary sentinel node ( ) . Intramammary node stag axillary node . Nonepithelial breast malignancy sarcoma lymphoma . Proven multicentric carcinoma one quadrant separate 4 centimeter . Paget 's disease nipple . Synchronous bilateral invasive noninvasive breast cancer . History DCIS invasive breast cancer . Surgical margin microscopically assess positive pathologic evaluation . Clear delineation target lumpectomy cavity possible . Any treatment radiation therapy , chemotherapy , and/or biotherapy administer currently diagnose breast cancer prior registration . The exception hormonal therapy , may give total 28 day anytime diagnosis registration . Prior breast thoracic radiotherapy condition . Collagen vascular disease , specifically dermatomyositis CPK level normal active skin rash , systemic lupus erythematosis , scleroderma . Pregnancy lactation time propose registration . Women reproductive potential must agree use effective nonhormonal method contraception therapy . Psychiatric addictive disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Contura</keyword>
	<keyword>Cancer</keyword>
	<keyword>Accelerated</keyword>
	<keyword>Partial</keyword>
	<keyword>Breast</keyword>
	<keyword>Irradiation</keyword>
</DOC>